CompletedPhase 1NCT00010192

Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer

Studying Acute lymphoblastic leukemia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
National Cancer Institute (NCI)
Principal Investigator
Pierluigi Porcu
Ohio State University
Intervention
rituximab(biological)
Enrollment
30 enrolled
Eligibility
18 years · All sexes
Timeline
2000

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00010192 on ClinicalTrials.gov

Other trials for Acute lymphoblastic leukemia

Additional recruiting or active studies for the same condition.

See all trials for Acute lymphoblastic leukemia

← Back to all trials